Conservative Groups Push to Overturn Inflation Reduction Act After $1M in PhRMA Contributions

In June 2024, a coalition of conservative organizations urged Republican congressional leaders to repeal key healthcare provisions in the Inflation Reduction Act, specifically its Medicare drug price negotiation measures. This push followed a failed lawsuit by the Pharmaceutical Research and Manufacturers of America (PhRMA), which claimed these provisions would lead to drug shortages, rationing, and reduced innovation.

Financial records reveal that in 2022, PhRMA contributed nearly $1 million to several of the same organizations that signed the repeal letter. These financial ties raise serious concerns about the influence of pharmaceutical money on efforts to overturn healthcare reforms designed to lower drug costs for Americans. The ongoing debate highlights the powerful role of industry lobbying in shaping policy and its potential impact on access to affordable healthcare.